The Licensure Landscape For Psychedelics Manufacturers
By Kimberly Chew and Jaime Dwight · August 27, 2024, 2:27 PM EDT
As the need for bulk manufacturing of psychedelic substances grows, manufacturers must prepare to navigate a regulatory labyrinth, as these Schedule I drugs, currently in clinical trials, are strictly regulated due...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login